TENATHAN
LOE Approachingbethanidine sulfate
NDAORALTABLET
Approved
May 1981
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 15h ago · AI intelligence enriched 2mo ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
TENATHAN (bethanidine sulfate) is an oral antihypertensive agent approved in 1981 for the treatment of hypertension. It is a small-molecule sympathomimetic that lowers blood pressure through peripheral adrenergic mechanisms. The drug is now in late-stage lifecycle with loss of exclusivity approaching.
LOE Approaching
With LOE approaching and competitive pressure at 30%, the commercial team is likely focused on defending market share and managing transition to generic competition rather than expansion.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on TENATHAN offers limited career acceleration as the product enters loss-of-exclusivity phase with minimal linked job openings. Professionals joining this team should focus on transitional skills (generic strategy, managed care, lifecycle management) rather than growth-stage innovation.
Brand ManagerProduct Manager
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.